This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Noted Geneticist Dr. Gail E. Herman Is Elected President Of The American College Of Medical Genetics And Genomics (ACMG)





BETHESDA, Md., March 28, 2013 /PRNewswire-USNewswire/ -- Gail E. Herman, MD, PhD, FACMG of Columbus, Ohio, is the new president of the American College of Medical Genetics and Genomics (ACMG), the national professional organization for clinical genetics professionals.

Dr. Herman takes over from Wayne W. Grody, MD, PhD, of Los Angeles, Calif., who completed his two-year term at the 2013 Annual Clinical Genetics Meeting in Phoenix, AZ, in March.

"I've been doing clinical genetics now for 30 years and while I think we've seen exciting new developments and technology before, the Human Genome Project, the first cloning of disease genes, I think there has never been a time as exciting or as likely to change the field of clinical medical genetics as right now. It's a really exciting time to be a geneticist and to be leading this medical professional organization," Dr. Herman said.

As president elect, Dr. Herman has spent much of her time helping the ACMG develop guidelines and best practice policies and procedures to keep up with the pace of the evolving technologies engulfing the field of medical genetics.

"I'm very proud of the policy statements and guidelines the College already has put out, or has in progress, related to next gen sequencing," Dr. Herman said. "I think we are clearly at the forefront of recommendations and helping to define policy going forward. There is a lot more to do and I would certainly like to see that continue during my term as president."

Dr. Herman graduated summa cum laude from Smith College, Northampton, MA with high honors in chemistry. She then entered the NIH-funded Medical Scientist Training Program at Duke University where she received a PhD in Biochemistry and an MD.

She completed residency training in Pediatrics and a fellowship in Genetics at Baylor College of Medicine, Houston, TX. She received a prestigious Lucille P. Markey Scholar Award in 1987 and joined the faculty in the Institute for (subsequently Department of) Molecular and Human Genetics, Baylor College of Medicine in 1988 as an Assistant and then Associate Professor with tenure. She is board certified in Pediatrics and Clinical and Clinical Biochemical Genetics (lifetime certificates).

Dr. Herman joined the faculty of the Department of Pediatrics at Nationwide Children's Hospital and The Ohio State University in 1997 and was promoted to Professor with tenure in 2000. She served as Director of the Division and Center for Molecular and Human Genetics in the Department of Pediatrics from 1998-2009 where she substantially expanded clinical pediatric genetics services, including a comprehensive metabolic diagnostic and treatment program.

She divides her time between her clinical practice of pediatric genetics and basic molecular genetics research. She has had funding from the NIH, as well as past foundation funding from the March of Dimes and Muscular Dystrophy Association. She is an author on more than 100 peer-reviewed publications and is an internationally recognized expert on Disorders of Cholesterol Biosynthesis.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs